Wordt geladen...
Novel therapies in thrombotic thrombocytopenic purpura
ESSENTIALS: The standard of care for patients with TTP remains daily plasma exchange in addition to immune suppressive therapy. Despite the improved treatment options for TTP, the acute mortality of TTP remains between 15‐20%. Caplacizumab reduces the time to platelet recovery and the exacerbation r...
Bewaard in:
| Gepubliceerd in: | Res Pract Thromb Haemost |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055500/ https://ncbi.nlm.nih.gov/pubmed/30046703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12066 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|